| Literature DB >> 21190554 |
Dawn Dore1, Ashleigh Martens, Stephen Quinn, Changhai Ding, Tania Winzenberg, Guangju Zhai, Jean-Pierre Pelletier, Johanne Martel-Pelletier, François Abram, Flavia Cicuttini, Graeme Jones.
Abstract
INTRODUCTION: Recent evidence suggests that bone marrow lesions (BMLs) play a pivotal role in knee osteoarthritis (OA). The aims of this study were to determine: 1) whether baseline BML presence and/or severity predict site-specific cartilage defect progression and cartilage volume loss; and 2) whether baseline cartilage defects predict site-specific BML progression.Entities:
Mesh:
Year: 2010 PMID: 21190554 PMCID: PMC3046535 DOI: 10.1186/ar3209
Source DB: PubMed Journal: Arthritis Res Ther ISSN: 1478-6354 Impact factor: 5.156
Characteristics of participants according to presence or absence of BMLs at baseline at each site*
| Age (year) | 63.2 (7.2) | 63.5 (7.2) | 63.3 (7.3) | 62.7 (6.3) | 63.1 (7.3) | 65.0 (6.4) | 63.3 (7.2) | 63.0 (7.6) |
| Male sex (%) | 49 | 53 | 49 | 57 | 50 | 46 | ||
| BMI (kg/m2) | 27.6 (4.4) | 28.0 (4.8) | 27.5 (4.5) | 28.5 (4.0) | 27.7 (4.5) | 26.6 (2.7) | 27.7 (4.5) | 27.2 (4.1) |
| Cartilage defects present baseline# (%) | ||||||||
| Cartilage defect increase (%) | ||||||||
| Cartilage volume baseline (mL) | 2,332 (580) | 2,352 (563) | 3,949 (1,135) | 4,024 (1,089) | 2,763 (681) | 2,687 (807) | 4,327 (1,194) | 4,351 (876) |
| Cartilage volume loss per annum (%) | ||||||||
| BML increase (%) | 11 | 17 | 11 | 12 | ||||
*Mean (standard deviation) except for percentages. Bold denotes a statistically significant result. P-values determined by t-test or chi-square test (where appropriate).
† P < 0.05.
‡ P < 0.01.
#Defined as grade 2 or higher.
BMI, body mass index; BMLs, bone marrow lesions; mL, millilitre.
Figure 1Baseline BMLs with cartilage defect increases and baseline cartilage defects with BML increases by site. (a) Proportion of participants whose cartilage defects increased in those with no baseline BML versus those with a baseline BML. (b) Proportion of participants whose BMLs increased in those with baseline cartilage defect grades 0 to 1 versus those with baseline cartilage defect grades 2 to 4.
Association between BMLs and cartilage defects
| Multivariable OR (95% CI)† | Multivariable OR (95% CI)‡ | |
|---|---|---|
| Medial tibial BMLs | ||
| Medial femoral BMLs | ||
| Lateral tibial BMLs | ||
| Lateral femoral BMLs | ||
| Medial tibial defects | ||
| Medial femoral defects | 2.0 (1.0, 4.1) | |
| Lateral tibial defects | 1.6 (0.8, 3.4) | |
| Lateral femoral defects |
Baseline BMLs (0 to 3) and site-specific increases in cartilage defects at the same site and baseline cartilage defects (0 to 4) and site-specific increases in BMLs at the same site.
Bold denotes a statistically significant result. *P < 0.05, **P < 0.01.
† Adjusted for age, sex, body mass index and baseline site-specific defects if BMLs and site-specific BMLs if defects. All P-values < 0.01.
‡ Further adjusted for meniscal extrusion and meniscal tear.
BMLs, bone marrow lesions; CI, confidence interval; OR, odds ratio.
Figure 2Baseline BMLs and cartilage defects with cartilage volume loss (% per annum). (a) Mean cartilage volume loss of participants with no BML at baseline versus those with a BML at baseline. (b) Mean cartilage volume loss of participants with baseline cartilage defect grades 0 to 1 versus those with baseline defect grades 2 to 4. Error bars represent standard error.
Baseline BMLs (0 to 3) and baseline cartilage defects (0 to 4) predicting absolute changes in cartilage volume
| Multivariable β (95% CI)† | Multivariable β (95% CI)‡ | |
|---|---|---|
| BMLs | -14.4 (-40.9, +12.1) | |
| Cartilage defects | -5.0 (-43.6, +33.7) | |
| BMLs | - | |
| Cartilage defects | -17.2 (-34.7, +0.4) | -17.2 (-34.8, +0.4)# |
| BMLs | - | |
| Cartilage defects | -12.6 (-34.2, +9.0) | -21.7 (-50.2, +6.8) |
| BMLs | - | |
| Cartilage defects | -12.3 (-29.7, +5.1) | -12.3 (-29.7, +5.1) |
Bold denotes a statistically significant result. *P < 0.05, **P < 0.01.
† Adjusted for age, sex, body mass index, baseline site-specific cartilage volume and defects if BMLs and BMLs if defects.
‡ Further adjusted for meniscal extrusion and meniscal tear.
#P = 0.056
β, beta-coefficient; BMLs, bone marrow lesions; CI, confidence interval.
Figure 3Interaction between baseline BMLs and baseline cartilage defects on tibial cartilage volume loss (% per annum). There was a significant interaction between (a) medial tibial BMLs and medial tibial cartilage defects; and (b) lateral tibial BMLs and lateral tibial cartilage defects, for site-specific cartilage volume loss.